Precigen director receives stock and option awards

PRECIGEN, INC. director Jeffrey B. Kindler received new equity awards as part of his board compensation.

Rhea-AI Filing Summary

PRECIGEN, INC. director Jeffrey B. Kindler received new equity awards as part of his board compensation. On March 10, 2026, he was granted 35,612 restricted stock units, each representing one share of common stock, which vest in full on March 10, 2027.

He was also granted options on 41,073 shares of common stock at an exercise price of $3.51 per share, expiring on March 10, 2036. In addition, he received 19,658 shares of common stock issued in lieu of an annual cash retainer of $69,000, bringing his directly held common stock to 130,261 shares.

Insider Trade Summary

Grant/Award: 96,343 shares

Grant/Award 3 txns

Insider KINDLER JEFFREY B

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	35,612	$0.00	$0.00
Grant/Award	Option to Purchase Common Stock (Right to Buy)	41,073	$0.00	$0.00
Grant/Award	Common Stock	19,658	$3.51	$69K

Holdings After Transaction: Restricted Stock Units — 35,612 contracts (Direct); Option to Purchase Common Stock (Right to Buy) — 41,073 contracts (Direct); Common Stock — 130,261 shares (Direct)

Footnotes (3)

1. F1. The shares were issued to the reporting person in lieu of an annual retainer of $69,000.
2. F2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.
3. F3. The RSUs vest in full on March 10, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did PRECIGEN (PGEN) director Jeffrey B. Kindler receive?

Jeffrey B. Kindler received a grant of 35,612 restricted stock units, stock options on 41,073 shares at $3.51 per share, and 19,658 shares of common stock issued as part of his annual board compensation package.

How many RSUs did Jeffrey B. Kindler receive from PRECIGEN (PGEN) and when do they vest?

He received 35,612 restricted stock units, each representing one share of PRECIGEN common stock. These RSUs vest in full on March 10, 2027, meaning he must remain eligible through that date to receive the underlying shares.

What are the terms of Jeffrey B. Kindler’s stock options from PRECIGEN (PGEN)?

Kindler was granted options on 41,073 shares of PRECIGEN common stock with an exercise price of $3.51 per share. The options become exercisable according to their terms and expire on March 10, 2036, providing long-dated equity exposure.

Why did PRECIGEN (PGEN) issue 19,658 shares of common stock to Jeffrey B. Kindler?

PRECIGEN issued 19,658 shares of common stock to Kindler in lieu of an annual cash retainer of $69,000. This structure compensates him for board service using equity rather than cash, further aligning his interests with shareholders.

How many PRECIGEN (PGEN) common shares does Jeffrey B. Kindler hold after these grants?

Following the March 10, 2026 transactions, Kindler directly holds 130,261 shares of PRECIGEN common stock. This total reflects the addition of 19,658 newly issued shares received as compensation for his annual director retainer.

What type of transaction is reported in this PRECIGEN (PGEN) Form 4 for Jeffrey B. Kindler?

All reported transactions are acquisitions coded “A,” reflecting grants or awards rather than open-market buying or selling. They include restricted stock units, stock options, and common shares issued as non-cash compensation for his role as a PRECIGEN director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/12/2026 - 04:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KINDLER JEFFREY B

(Last) (First) (Middle)

20374 SENECA MEADOWS PARKWAY

(Street)

GERMANTOWN MD 20876

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PRECIGEN, INC. [ PGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		A		19,658	A	$3.51(1)	130,261	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	03/10/2026		A		35,612		(3)	(3)	Common Stock	35,612	$0	35,612	D
Option to Purchase Common Stock (Right to Buy)	$3.51	03/10/2026		A		41,073		03/10/2026	03/10/2036	Common Stock	41,073	$0	41,073	D

Explanation of Responses:

1. The shares were issued to the reporting person in lieu of an annual retainer of $69,000.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

3. The RSUs vest in full on March 10, 2027.

	/s/ Jeffrey B. Kindler, by Donald P. Lehr, as attorney-in-fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.